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OBJECTIVE — 1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in
diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in
a lowered plasma concentration. As a low renal threshold for glucose has been described in
hepatocyte nuclear factor-1 (HNF-1) maturity-onset diabetes of the young (MODY), the
1,5-AGlevelmaybealteredinthesepatients.Thepurposeofthisstudywastoassessthe1,5-AG
levels in patients with HNF-1 MODY and in type 2 diabetic subjects with a similar degree of
metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1
MODY.
RESEARCH DESIGN AND METHODS — We included 33 diabetic patients from the
Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and
47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic
assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate
1,5-AG as a screening marker for HNF-1 MODY.
RESULTS — The mean 1,5-AG plasma concentration in diabetic HNF-1 mutation carriers
was5.9g/ml,anditwaslowerthanthatintype2diabeticpatients(11.0g/ml,P0.003)and
in nondiabetic control subjects (23.9 g/ml, P  0.00005). The ROC curve analysis revealed
85.7% sensitivity and 80.0% speciﬁcity of 1,5-AG in screening for HNF-1 MODY at the
criterion of 6.5 g/ml in patients with an A1C level between 6.5 and 9.0%.
CONCLUSIONS — 1,5-AG may be a useful biomarker for differential diagnosis of patients
with HNF-1 MODY with a speciﬁc range of A1C, although this requires further investigation.
However, the clinical use of this particle in diabetic HNF-1 mutation carriers for metabolic
control has substantial limitations.
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,5-anhydroglucitol (1,5-AG) is a
monosaccharide that shows a struc-
tural similarity to glucose. Its main
source in humans is dietary ingestion,
particularly meats and cereals (1). In
addition, 10% of 1,5-AG is derived
from endogenous synthesis. 1,5-AG is
generally not metabolized, and in
healthy subjects it achieves a stable
plasma concentration that reﬂects a
steady balance between ingestion and
urinary excretion (1).
1,5-AG is reabsorbed in renal tubules
by an AG/fructose/mannose common
transport system that is distinct from the
major glucose reabsorption system (2,3).
In hyperglycemic conditions, the excess
of glucose is reabsorbed owing to chemi-
cal similarity not only by its own speciﬁc
active transporters, but also by the AG/
fructose/mannose transporter; therefore,
it competes with 1,5-AG. Subsequently,
1,5-AG urinary excretion is increased
during hyperglycemia, and it results in a
lowered plasma concentration (4). This
explains its low plasma level in patients
withpoorlycontrolleddiabetes.Thispar-
ticle was established in clinical practice as
a short-term marker of metabolic control,
and recently it has been investigated as a
marker of postprandial hyperglycemia
(5,6). In contrast to A1C, it reﬂects
changes in glycemic control over a period
of 1–2 weeks (5).
The 1,5-AG excretion rate depends
on the renal threshold for glucose (7).
Thus, its clinical usefulness in evaluation
of some groups of patients, for example,
pregnant women and subjects with end-
stagerenaldisease,isobvious(7,8).Inter-
estingly,thedecreasedrenalthresholdfor
glucose was observed in patients with he-
patocytenuclearfactor-1(HNF-1)ma-
turity-onset diabetes of the young
(MODY), formerly classiﬁed as MODY3,
and in nondiabetic mutation carriers of
this gene (9,10). Diabetes that results
from HNF-1 mutations is usually ac-
companied by extrapancreatic features.
One of them is a tubulopathy that results
in a low renal threshold for glucose. An
animal model suggests that it is caused by
decreased expression of sodium-glucose
cotransporter 2, a low-afﬁnity, high-
capacity transporter in proximal renal tu-
bules (11). Thus, hypothetically, the
increased glucose load in renal tubules in
these patients may cause stronger compe-
tition with 1,5-AG for reabsorption and,
subsequently, increased urinary loss.
Moreover, one cannot exclude the impact
of HNF-1 mutations on the expression
of the AG/fructose/mannose transporter.
Therefore, in HNF-1 MODY, lower
plasma concentrations of 1,5-AG com-
paredwiththoseinothertypesofdiabetes
can be expected at a similar A1C. In the
scenario of a very low 1,5-AG level, this
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candidate biochemical marker for this
monogenic type of diabetes, which may
have considerable clinical implications
and enable screening for patients with
HNF-1 MODY in large cohorts, poten-
tially avoiding the expensive and labori-
ous technique of direct gene sequencing.
In this study, we compared 1,5-AG
plasma concentrations in diabetic
HNF-1 mutation carriers with those in
patients with type 2 diabetes and in non-
diabetic subjects.
RESEARCH DESIGN AND
METHODS— The Nationwide Regis-
try of MODY has been established at the
Department of Metabolic Diseases, Jagiel-
lonian University Medical College, Kra-
kow, Poland. Details of the inclusion
criteria and the examination were re-
ported previously (12). So far, 57
HNF-1 mutation carriers have been
identiﬁed. We contacted 47 adult sub-
jects from this group, and 41 agreed to
enter this study. The following exclusion
criteria were used: pregnancy, liver cir-
rhosis, hypo- or hyperalimentation, ste-
roid therapy, gastrectomy, and elevated
serumcreatininelevel.Basedonthesecri-
teria, we excluded four patients because
of increased serum creatinine concentra-
tion (i.e., 97 mol/l, the upper refer-
ence limit for the assay). Thus, the study
group for examination consisted of 37
subjects. The number of patients with
HNF-1 MODY, with diabetes diagnosed
according to World Health Organization
criteria, was 33, whereas 4 subjects were
normoglycemic in the fasting condition
and were classiﬁed as nondiabetic sub-
jects, which is also supported by the fact
that they all had A1C levels within the
normalrange(6.0%).Twomoregroups
were examined. The ﬁrst group, 47 ap-
parently healthy control subjects who
were normoglycemic in the fasting condi-
tion, contained spouses of patients with
MODY and volunteers from the medical
personneloftheDepartmentofMetabolic
Diseases. The second group included 43
patientswithtype2diabetesdiagnosedat
age 35 years for whom no insulin ther-
apy was used for at least 2 years after di-
agnosis, ascertained as previously
described (13). The same exclusion crite-
riawereusedasfortheMODYgroup.The
studyprotocolandinformedconsentpro-
cedureswereapprovedbytheethicscom-
mittee of Jagiellonian University, Medical
College and were concordant with the
Declaration of Helsinki.
The blood samples were collected in
fasting conditions for biochemical evalu-
ation. Serum and EDTA-plasma were ob-
tained by spinning at 3,500 rpm and
stored at 80°C. The 1,5-AG concentra-
tion was measured in EDTA-plasma sam-
ples with an enzymatic, colorimetric
method using GlycoMark chemicals
(Tomen America) by Nippon Kayaku To-
kyo Co. (Tokyo, Japan) (14). A1C was
measured with high-performance liquid
chromatography (Bio-Rad). Fasting glu-
cose levels were determined by an enzy-
matic technique (automated analysis
glucose GOD-PAP method; Boehringer
Mannheim). Serum creatinine concentra-
tions were measured with the Jaffe
method.
Comparisons were made with the 
2
or Fisher’s exact test, where applicable,
for frequencies of qualitative traits. For
quantitative traits, Student’s t test or
ANOVA was used with the Tukey post
hoc test when data ﬁt into a normal dis-
tribution. Otherwise, the Mann-Whitney
or the Kruskal-Wallis test was used. The
dataforwhichtheKruskal-Wallistestwas
signiﬁcant were further analyzed with a
nonparametricmultiplecomparisonSteel
test. Normality was tested with the Kol-
mogorov-Smirnov test. Spearman’s rank
correlation was used to test the relation-
ships between quantitative traits. Multi-
ple linear regression was applied to
determine independent predictors for the
1,5-AG level. These predictors were in-
cluded as covariates in a general linear
model analysis performed in all study
groups and in the diabetic groups. Com-
putations were performed with MiniTab
14.20 statistical software and the R Lan-
guage and Environment, version 2.4.1.
P  0.05 was considered signiﬁcant. In
analysis of plasma 1,5-AG measurements
as a biochemical test for HNF-1 MODY,
the test parameters were calculated and
receiver operating characteristic (ROC)
curve analysis was performed with Med-
Calc 9.3.8.0 statistical software.
RESULTS— Clinical characteristics of
thestudygroupsarepresentedinTable1.
Both diabetic groups were similar for tra-
ditional measures of metabolic control
such as fasting glucose and A1C. They
Table 1—Clinical characteristics of patients with type 2 diabetes and HNF-1 MODY and nondiabetic control subjects
Type 2
diabetes
P value
(post hoc)*
HNF-1
MODY
P value
(post hoc)* Control P value
n 43 NA 33 NA 47 NA
Sex (% female) 65.1 NA 75.8 NA 61.7 0.41†
Age (years) 56.2 	 9.3 0.0005‡ 42.9 	 16.1 0.68‡ 45.5 	 15.3 0.0005§
BMI (kg/m
2) 35.1 	 7.9 0.0005‡ 23.0 	 3.4 0.13‡ 25.5 	 4.2 0.0005§
Diabetes duration
(years)
8.8, 6.0, 6.0 NA 17.3, 16.0, 12.2 NA NA 0.004
Fasting glucose
(mmol/l)
7.6, 7.5, 1.7 0.62¶ 7.9, 7.4, 1.9 0.00005¶ 4.7, 4.8, 0.6 0.00005**
A1C (%) 7.6, 7.1, 1.4 NA 7.6, 7.7, 1.1 NA NA 0.77
% OHA 62.8 NA 45.5 NA NA 0.13†
Creatinine
(mol/l)
70.7 	 12.7 NA 69.2 	 12.6 NA 69.8 	 10.6 0.86§
1,5-AG (g/ml) 11.0, 11.5, 6.7 0.003¶ 5.9, 2.6, 4.3 0.00005¶ 23.9, 24.5, 4.9 0.00005**
Data are means 	 SD or mean, median, quartile deviation. % OHA is the proportion of patients treated with oral hypoglycemic agents; the rest of the subjects were
insulintreatedinmonotherapyorincombinationwithOHAs.Age,BMI,andserumcreatinineconcentrationﬁtintonormaldistribution.*Non–normallydistributed
data, for which the Kruskal-Wallis test was signiﬁcant, were further analyzed with Steel’s nonparametric multiple comparison test. †
2 test. ‡Tukey post hoc test.
§One-way ANOVA. Mann-Whitney test. ¶Steel test. **Kruskal-Wallis test. NA, not applicable.
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tesduration,whichisinlinewiththeway
both groups were deﬁned. Subjects from
all groups also had an almost identical se-
rum creatinine level.
The mean 1,5-AG plasma concentra-
tioninthediabeticHNF-1mutationcar-
riers group was 5.9 g/ml (median 2.6
g/ml,quartiledeviation4.3),whereasin
the type 2 diabetic group it was 11.0
g/ml (11.5 g/ml, 6.7) and in the non-
diabetic control group it was 23.9 g/ml
(24.5 g/ml, 4.9). There was a highly sig-
niﬁcant difference between the MODY
group and the control group (P 
0.00005) and between the MODY and
type 2 diabetic groups (P  0.003). To
justify application of a parametric ap-
proach in further analysis, the data were
reevaluated with ANOVA and the Tukey
test, results of which were also signiﬁcant
(P  0.00005 and P  0.013, respec-
tively). In four HNF-1 normoglycemic
mutation carriers, the mean 1,5-AG level
was 21.1 g/ml (range 16.7–32.9 g/ml)
and was not different from the level in the
control group (P  0.32). The mean age
of the four subjects was 24.7 years, mean
BMI was 21.0 kg/m
2, and mean A1C was
5.6%.
The 1,5-AG concentration was lower
in women than in men in the control
group (21.5 vs. 27.7 g/ml, P  0.003),
whereas there were no signiﬁcant differ-
ences between sexes in the MODY and
type 2 diabetic groups (P  0.71 and P 
0.91, respectively). In the MODY group,
the 1,5-AG level signiﬁcantly correlated
only with the A1C level (
 0.72, P 
0.0005), whereas in the type 2 diabetic
group there was signiﬁcant correlation of
the 1,5-AG level with A1C (
 0.72,
P0.0005)andageofdiabetesdiagnosis
(
0.36, P  0.018). In multiple linear
regression the A1C level remained the
onlysigniﬁcantpredictorfor1,5-AG(P
0.0005). In the nondiabetic control
group, the 1,5-AG concentration signiﬁ-
cantly correlated with age (
 0.52,
P  0.0005) and BMI (
 0.34, P 
0.02). In the multiple regression model,
the only signiﬁcant predictor was age
(P  0.004).
The general linear model for 1,5-AG
concentration as a dependent variable
was applied in the three study groups
combined (R
2  52.1%). The differences
in 1,5-AG level between the study groups
remained signiﬁcant (P  0.0005), and
age was a signiﬁcant covariable (P 
0.044).Inthediabeticstudygroups(R
2
53.2%),thegenerallinearmodelrevealed
asigniﬁcantdifferencein1,5-AGlevelbe-
tween type 2 diabetes and HNF-1
MODY (P  0.006), with A1C level as a
signiﬁcant covariable (P  0.0005).
The ROC curve analysis was per-
formed in diabetic patients: 33 with
HNF-1 MODY and 43 with type 2 dia-
betes. Area under the ROC curve (AUC)
Figure 1—Individual value plot of 1,5-AG concentrations against A1C levels in HNF-1 MODY
and type 2 diabetic groups.  , adult MODY patients; f, type 2 diabetic patients; E, nondiabetic
HNF-1 mutation carriers.
Figure 2—ROC curve analysis for the diabetic patients with normal serum creatinine concentra-
tions and A1C levels 6.5 and 9.0%. A: ROC curve. Marker represents optimal value. B:
Sensitivity and speciﬁcity plotted against a cutoff value of plasma 1,5-AG concentration. Addi-
tional vertical gridlines represent the optimal cutoff value of 6.5 g/ml.
1,5-AG and HNF-1 MODY
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optimal sensitivity and speciﬁcity to test
for MODY were 72.7% (54.5–86.7%)
and65.1%(49.1–79.0%),respectively,at
a criterion of 6.6 g/ml of plasma 1,5-
AG. To further improve the parameters of
thetest,weperformedadditionalanalyses
with a narrowed A1C range based on the
plot showing relationships between A1C
and 1,5-AG in diabetic groups (Fig. 1).
Because type 2 diabetic patients with an
A1C level 9.0% had a very low 1,5-AG
level, similar to subjects with HNF-1
MODY, we ﬁrst excluded all individuals
with A1C above this value (5 patients
with MODY and 10 with type 2 diabetes,
respectively). This resulted in better ROC
curve analysis outcomes, particularly the
test speciﬁcity. The AUC was 0.823
(0.704–0.909), and optimal sensitivity
and speciﬁcity at the criterion of 6.6
g/ml1,5-AGwere71.4%(51.3–86.7%)
and 84.85% (68.1–94.8%), respectively.
Additionally,weexcluded7patientswith
MODY and 13 with type 2 diabetes who
had A1C 6.5% because of a lack of cor-
relation of 1,5-AG with A1C in both
groups(P0.34forMODYandP0.44
for type 2 diabetes). This exclusion im-
proved the test speciﬁcity and resulted in
the following parameters: AUC 0.887
(0.749–0.964) and optimal sensitivity at
the criterion for MODY of 6.5 g/ml
1,5-AG 85.7% (63.6–96.8%) and speci-
ﬁcity 80.0% (56.3–94.1%). Figure 2
shows this ROC curve analysis in the
group of patients with an A1C range be-
tween 6.5 and 9.0%.
CONCLUSIONS — Here we report
for the ﬁrst time the plasma 1,5-AG levels
in patients with HNF-1 MODY. We ob-
served that the levels of 1,5-AG in this
group were signiﬁcantly lower than those
in type 2 diabetic subjects with similar
glycemic control as assessed by A1C lev-
els and fasting glucose level. We were
promptedtoperformthisstudybyanear-
lier description of decreased renal thresh-
old and increased glycosuria in HNF-1
mutationcarriers(9,10).Themajorcause
of low 1,5-AG levels in diabetic HNF-1
mutation carriers is, as in other diabetic
patients, most likely its competition in
the renal tubule with a large amount of
glucose for the AG/fructose/mannose
transporter (3). However, in HNF-1
mutation carriers, the threshold for glu-
cosuria is lower, and therefore the ex-
cessive glucose in the renal tubule
would be expected to result in greater
decrements in 1,5-AG. One cannot rule
out, however, that the additional mech-
anism associated with the impaired ex-
pression of this transporter is a direct
resultofamutationintheHNF-1 gene
encoding a transcription factor present
in kidney. The conﬁrmation of this later
hypothesis will require expression gene
experiments.
Our observation may have two im-
portant clinical implications. First,
1,5-AG measurements have limited use-
fulness in HNF-1 MODY as a marker of
metabolic control. 1,5-AG is accepted by
theU.S.FoodandDrugAdministrationas
a tool of monitoring glycemic control of
diabetic patients. There were already
some groups of patients described for
whom 1,5-AG should not be recom-
mended as a diabetes control measure
owing to a low renal threshold for glu-
cose, such as pregnant women and pa-
tients with end-stage renal disease (7,8),
although some promising attempts of its
useingestationaldiabetesweredescribed
(15). In addition, there were some efforts
to use 1,5-AG as a screening tool in dia-
betes (16,17). It should be emphasized,
however, that no scientiﬁc diabetes orga-
nization recommended it for this pur-
pose. If, however, 1,5-AG is accepted as a
screening tool for diabetes at any time in
the future, this should not include situa-
tionsinwhichtherenalthresholdforglu-
cose is altered, such as HNF-1 MODY.
At the same time, our observation
pointsto1,5-AGasapotentialdifferential
diagnosis biomarker for MODY associ-
ated with HNF-1 mutations. The mea-
surementofplasma1,5-AGlevelseemsto
havehighsensitivityandspeciﬁcitytodif-
ferentiate between HNF-1 MODY and
type 2 diabetes as long as A1C values are
between6.5and9.0%.Itshouldbenoted
that most of the patients seen in everyday
clinical practice fall into this range. Our
studyshouldbeperhapscriticizedfordis-
secting the data to improve the ROC
curve and for choosing an arbitrary range
of A1C for this analysis. As shown in Fig.
1, all individuals, MODY patients, and
type 2 diabetic subjects with A1C 9.0%
had very low 1,5-AG levels, probably due
to a massive overload of renal tubules by
glucose, and thus the marker is not spe-
ciﬁcinthisrangeofA1C.Theexclusionof
subjects with low A1C values is justiﬁed
by the fact that some degree of hypergly-
cemiaisnecessarytocauseglycosuriaand
a subsequent fall in 1,5-AG level. The re-
nal threshold in patients with HNF-1
MODY was measured at a mean whole
blood glucose level of 6.5 mmol/l (the
equivalent of 7.4 mmol/l in plasma)
(9,10). In another study, during an oral
glucose tolerance test, glycosuria was de-
tected only in nondiabetic subjects with
HNF-1 mutations and with impaired
glucose tolerance (10). An additional ar-
gument constitutes a lack of correlation
between A1C and 1,5-AG levels among
subjects with well-controlled diabetes in
our study and in an earlier report (18).
Nevertheless, the speciﬁc range of A1C
forwhich1,5-AGisausefulbiomarkerfor
differential diagnosis will require further
conﬁrmation. Interestingly, all nondia-
betic HNF-1 mutation carriers had lev-
els of marker in the range of the 10th–
90th percentile of the control subjects,
indicating that 1,5-AG measurement is
not useful for predictive testing.
Lack of postprandial hyperglycemia
data in the subjects examined is a limita-
tion of our study. As a consequence, we
cannot entirely rule out the possibility
that a higher degree of postprandial hy-
perglycemia in HNF-1 MODY patients
might have partially contributed to the
observed large, almost twofold difference
in 1,5-AG level between both diabetic
groups. There are, however, important
indirect arguments on the key effect of
renal tubulopathy. First, it was shown in
two other clinical groups, pregnant
women and patients with end-stage renal
disease, that the renal threshold for glu-
cose, which is substantially different from
normal, seriously inﬂuenced the circulat-
ing 1,5-AG level (7,8). Because renal tu-
bulopathy in HNF-1 MODY has been
well documented previously (9,10), its
inﬂuence on 1,5-AG seems inevitable.
Second, our diabetic study groups were
not only identical for A1C but also very
similar for fasting glucose. Because the
A1C level is inﬂuenced by both postpran-
dial and fasting plasma glucose (19), it is
very unlikely that putative signiﬁcantly
higher postprandial hyperglycemia had a
substantial, if any, contribution to this
huge difference in the 1,5-AG level.
HNF-1genemutationcarrierswerepre-
viously reported as having higher post-
challenge hyperglycemia compared with
glucokinase mutation carriers (MODY2)
(20). The latter group, however, is very
speciﬁc and unusual, with its own very
low postchallenge glucose increase (2–3
mmol at 2 h). No published data support
a notion that HNF-1 MODY is charac-
terized by greater postprandial hypergly-
cemia than type 2 diabetes. Previously, a
particularly high effect of postprandial
hyperglycemia (as assessed by a continu-
Skupien and Associates
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1,5-AG level was described in a group of
diabetic patients with moderately con-
trolleddiabetes(withA1C8%);mostof
these patients had type 1 diabetes, which
is characterized by absolute insulin deﬁ-
ciency (6). The phenomenon of a greater
contribution of postprandial hyperglyce-
mia to overall glycemic control in such
patients with moderately controlled dia-
betes was described earlier (19). The
comparison done between our diabetic
groups with respect to 1,5-AG level in-
cluded patients with a variable degree of
glycemic control and also those with A1C
values 8% (30% of MODY subjects),
inwhomtheimpactoffastingplasmaglu-
cose is larger. Our study should also per-
haps be criticized for choosing type 2
diabetic patients for the comparison, as
theirclinicalcharacteristicsweredifferent
from those of patients with HNF-1 mu-
tations and, thus, some variables could
haveanimpactonindividualglucosepro-
ﬁles and therefore contribute to lower
1,5-AG despite seemingly equal A1C val-
ues. Two more groups of patients should
be considered. The ﬁrst group is subjects
withotherformsofMODY.Amongthose,
thecarriersofHNF-4(MODY1)seemto
be the most appropriate for the compari-
son because of its clinical similarity to
HNF-1 MODY, relatively high fre-
quency,andthelackofdataonthealtered
glucose renal threshold (21,22). How-
ever,thefamiliesfromThePolishNation-
wide Registry of MODY have not been
systematically tested for mutations in this
gene, and we do not have a cohort of an
appropriate size in this ethnic group. A
second group that might be considered
for the comparison of 1,5-AG with the
diabetic HNF-1 mutation carriers is type
1 diabetic patients. There are, however, al-
ready biomarkers available to differentiate
between MODY and type 1 diabetes, such
as islet-speciﬁc antibodies and C-peptide.
In addition, it is difﬁcult to provide
positiveandnegativepredictivevaluesfor
the test based on serum 1,5-AG measure-
ments. It would require a different study
designinwhichtestingisprospectiveand
wouldnot,asinourstudy,involvetesting
two discrete groups. Thus, we propose
this as a future study. We believe that an
applicationfor1,5-AGasamarkerfordif-
ferentiation between other MODY sub-
types or in young type 2 diabetic subjects
will be found eventually. The relative
prevalence of HNF-1 MODY may con-
stitute from one-third to two-thirds of
families with early-onset autosomal dom-
inant diabetes (23,24) and about 8% of
young patients with type 2 diabetes (25).
This should give a 1,5-AG–based test ap-
propriate positive and negative predictive
values. Finally, we should acknowledge
that a relatively small number of HNF-1
MODY patients were examined.
Some general observations should
also be emphasized. First, as expected,
the1,5-AGconcentrationwasstronglyin-
versely correlated with the A1C level in
diabetic patients from both groups. The
inﬂuence of sex and age on 1,5-AG levels
was observed previously in control sub-
jects (14,18) but, as with our data, not in
the diabetic study groups, as reported
from other populations (18). The creati-
nine level did not inﬂuence plasma
1,5-AG concentration in these study
groups: all three groups had normal cre-
atininelevels.Themeanlevelof1,5-AGin
thecontrolgroupwasslightlyhigherthan
that in an American reference population
(14), which may be caused by different
nutritional habits in the Polish popula-
tion,especiallyhigherconsumptionofce-
real food.
In summary, we conclude that
1,5-AG may be a useful biomarker for the
differential diagnosis of patients with
HNF-1 MODY with a speciﬁc range of
A1C, although it requires further investi-
gation in larger sets of patients and other
diabetic groups, as well as direct assess-
ment of the relative contribution of the
low renal threshold for glucose and post-
prandial hyperglycemia. However, the
clinical use of this particle in diabetic
HNF-1 mutation carriers for metabolic
control has substantial limitations.
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